Petr Vitalievich Glybochko

Petr Vitalievich Glybochko

Auto-generated profile, based on publicly available information

Petr Vitalievich Glybochko

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2019 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
VAViktoria Andreeva
Viktoria Andreeva
AVAndrey Z. Vinarov
Andrey Z. Vinarov
IYIlya Yaroslavsky
Ilya Yaroslavsky
AKAnastasia Kovalenko
Anastasia Kovalenko
AVAlexander Vybornov
Alexander Vybornov
VGValentin Gapontsev
Valentin Gapontsev

18 July 2019 in World Journal of Urology
Verified
Journal Article
Closed access
FJFlorian Janisch
Florian Janisch
SSShahrokh F. Shariat
Shahrokh F. Shariat
PBPascal Baltzer
Pascal Baltzer
HFHarun Fajkovic
Harun Fajkovic
SKShoji Kimura
Shoji Kimura
MAMohammad Abufaraj
Mohammad Abufaraj

1 November 2018 in Urology
Verified
Journal Article
Closed access
DEDmitry Enikeev
Dmitry Enikeev
PGPetr Glybochko
Petr Glybochko
LRLeonid Rapoport
Leonid Rapoport
JGJeffrey Gahan
Jeffrey Gahan
MGMagomed Gazimiev
Magomed Gazimiev
MTMark Taratkin
Mark Taratkin

1 January 2019 in Journal of Endourology
Verified
Journal Article
Closed access
DEDmitry Enikeev
Dmitry Enikeev
ZOZhamshid Okhunov
Zhamshid Okhunov
LRLeonid Rapoport
Leonid Rapoport
MTMark Sergeevich Taratkin
Mark Sergeevich Taratkin
MEMikhail Enikeev
Mikhail Enikeev
PGPetr Vitalievich Glybochko
Petr Vitalievich Glybochko
Introduction: The objective of this study was to assess the efficacy and safety of novel thulium fiber laser enucleation of the prostate (ThuFLEP) vs conventional open simple retropubic prostatectomy (OP) for large volume benign prostatic hyperplasia (BPH). Methods: We performed a retrospective review of patients who underwent surgical treatment for large volume BPH (>80 cc) from 2015 to 2017. Preoperative patient examination included the assessment of functional parameters: International Prostate Symptom Score (IPSS), quality of life (QoL), maximum urine flow rate (Q max ), and postvoid residual urine volume. The hemoglobin level was measured before and after the operation. Results: A total of 130 patients were included in the study. Of these, 40 patients underwent OP, and 90 patients underwent ThuFLEP. Groups were similar in terms of preoperative functional parameters (IPSS, QoL, and Q max ). The mean operative time was comparable for both procedures ( p = 0.285) as well as the mass of adenomatous tissue resected ( p = 0.412). Resection speed was comparable (OP—0.9 vs ThuFLEP—1.0 g/min, p = 0.52). Patients in OP had significantly longer catheterization time and length of hospital stay (9.0 days vs 3.3 days, p < 0.001). At 6 months, stress urinary incontinence rate were 1.1% after ThuFLEP and 2.5% after OP. Conclusions: Despite the equally high efficacy of both modalities for infravesical obstruction due to BPH, ThuFLEP is a minimally invasive modality that is associated with a shorter hospital stay, a significantly greater return to normal activities, and a considerable reduction in rehabilitation time. Our results demonstrated that the ThuFLEP is a highly efficacious, minimally invasive modality for the management of BPH in large volume glands (>80 cc).

1 December 2017 in Journal of Urology
Verified
Journal Article
Closed access
LKLaura-Maria Krabbe
Laura-Maria Krabbe
BHBarbara Heitplatz
Barbara Heitplatz
SPSina Preuss
Sina Preuss
RHRyan C. Hutchinson
Ryan C. Hutchinson
SWSolomon L. Woldu
Solomon L. Woldu
VMVitaly Margulis
Vitaly Margulis
We investigated the prognostic value of PD-1 and PD-L1 expression in patients with high grade upper tract urothelial carcinoma. Tissue microarrays of 423 patients treated with extirpative surgery for high grade upper tract urothelial carcinoma from the International Upper Tract Urothelial Carcinoma collaboration were stained for PD-1 and PD-L1 using antibodies, including Cell Marque™ NAT105 diluted 1:250 and prediluted E1L3N® via immunohistochemistry. A 1% or greater staining rate of tumor infiltrating lymphocytes (PD-1) and tumor cells (PD-L1) was considered positive. Univariate and multivariate analyses were performed to assess independent prognosticators of survival outcomes. Median patient age was 70.0 years and median followup was 37.0 months. PD-1 and PD-L1 were positive in 37.2% and 26.2% of patients, respectively. PD-1 positivity was significantly associated with adverse pathological characteristics while PD-L1 positivity was associated with favorable pT stage. On univariate analysis PD-1 expression was associated with worse recurrence-free, cancer specific and overall survival. On multivariate analysis PD-1 expression was an independent prognosticator of cancer specific survival (HR 1.7, 95% CI 1.03-2.66, p = 0.039) and overall survival (HR 1.5, 95% CI 1.05-2.24, p = 0.029) but not recurrence-free survival (HR 1.4, 95% CI 0.9-2.16, p = 0.139). On univariate analysis PD-L1 expression was not significantly associated with survival outcomes. However, on multivariate analysis in patients with organ confined disease (pT2 or less, pN0/x and cM0), PD-L1 positivity was an independent prognosticator of recurrence-free survival (HR 0.2, 95% CI 0.06-0.98, p = 0.046) and overall survival (HR 0.3, 95% CI 0.11-0.63, p = 0.003). PD-1 positivity of tumor-infiltrating lymphocytes was associated with adverse pathological criteria and independent prognostication of worse survival outcomes. PD-L1 positivity of tumor cells was an independent prognosticator of favorable survival outcomes in cases of organ confined disease.

1 November 2020 in Journal of Endourology
Verified
Journal Article
Closed access
DEDmitry Enikeev
Dmitry Enikeev
MTMark Taratkin
Mark Taratkin
RKRoman Klimov
Roman Klimov
JIJasur Inoyatov
Jasur Inoyatov
CACamilla Azilgareeva
Camilla Azilgareeva
PGPetr Glybochko
Petr Glybochko
Objective: To compare the efficacy of the standard and higher frequency regimens for superpulsed thulium fiber laser (SP TFL) retrograde intrarenal surgery (RIRS). Materials and Methods: A prospective study of patients with renal calculi of 10–30 mm was performed. For RIRS, we used the SP TFL (NTO IRE-Polus, Russia) and a 9.5F flexible ureteroscope with 270° deflection and 3.6F working channel. Retropulsion and visibility were assessed based on the surgeon's feedback using three-point Likert scales. The stone-free rate was assessed at 3 months with CT. Results: A total of 40 patients were included in the study with a mean age of 56 years, mean stone density of 880 ± 381 HU, mean stone size of 16.5 ± 6.8 mm, and median stone volume of 883 (interquartile range 606–1664) mm 3 . Both ablation efficacy and speed were higher in the 200-Hz mode (2.7 J/mm 3 vs 3.8 J/mm 3 and 5.5 mm 3 /second vs 8.0 mm 3 /second, respectively); moreover, the higher frequency correlated with increased ablation speed ( r = −0.21, p = 0.019). However, both increased energy and frequency did not lead to increase of laser-on time or intraoperative complication rates. Conclusions: SP TFL is able to effectively disintegrate stones during RIRS with minimal complication rates. The use of higher frequency regimens showed higher efficacy and ablation speed and was not associated with increased complication rates.